Integer (NYSE:ITGR) Receives Buy Rating from Benchmark

Benchmark restated their buy rating on shares of Integer (NYSE:ITGR) in a research report released on Friday, Benzinga reports. The brokerage currently has a $130.00 price objective on the medical equipment provider’s stock.

Several other analysts have also recently weighed in on ITGR. Bank of America raised Integer from a neutral rating to a buy rating and raised their price target for the company from $105.00 to $135.00 in a report on Monday, April 15th. CL King initiated coverage on shares of Integer in a research note on Thursday, March 14th. They issued a buy rating and a $137.00 target price on the stock. Finally, KeyCorp boosted their price target on shares of Integer from $123.00 to $139.00 and gave the stock an overweight rating in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $120.50.

Integer Trading Down 1.4 %

Shares of ITGR opened at $109.58 on Friday. The business’s 50-day moving average price is $113.11 and its 200-day moving average price is $100.07. The company has a quick ratio of 1.71, a current ratio of 3.32 and a debt-to-equity ratio of 0.76. Integer has a twelve month low of $69.40 and a twelve month high of $123.99. The stock has a market cap of $3.67 billion, a PE ratio of 37.92, a P/E/G ratio of 1.52 and a beta of 1.10.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. The business had revenue of $414.80 million for the quarter, compared to analyst estimates of $412.78 million. Integer had a net margin of 6.01% and a return on equity of 11.25%. Integer’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.87 EPS. On average, equities analysts forecast that Integer will post 5.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ITGR. Handelsbanken Fonder AB raised its position in Integer by 1.7% in the 4th quarter. Handelsbanken Fonder AB now owns 5,837 shares of the medical equipment provider’s stock worth $578,000 after purchasing an additional 100 shares during the period. Cornercap Investment Counsel Inc. increased its holdings in shares of Integer by 1.0% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 12,014 shares of the medical equipment provider’s stock worth $1,190,000 after buying an additional 121 shares during the period. Arizona State Retirement System lifted its stake in shares of Integer by 1.4% in the 3rd quarter. Arizona State Retirement System now owns 9,474 shares of the medical equipment provider’s stock valued at $743,000 after acquiring an additional 131 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in Integer by 10.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 132 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in Integer by 1.5% in the 3rd quarter. Janney Montgomery Scott LLC now owns 9,507 shares of the medical equipment provider’s stock worth $746,000 after purchasing an additional 142 shares during the period. 99.29% of the stock is owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.